索引于
  • 打开 J 门
  • Genamics 期刊搜索
  • 学术钥匙
  • 期刊目录
  • 中国知网(CNKI)
  • 乌尔里希的期刊目录
  • 参考搜索
  • 哈姆达大学
  • 亚利桑那州EBSCO
  • 期刊摘要索引目录
  • OCLC-WorldCat
  • 普布隆斯
  • 日内瓦医学教育与研究基金会
  • 欧洲酒吧
  • 谷歌学术
分享此页面
期刊传单
Flyer image

抽象的

Therapeutic Efficacy of Spleen-Derived Mesenchymal Stem Cells in Mice with Acute Pancreatitis

Ya-Chin Hou, Chen-Fang Huang, Hao-Chen Wang, Yu Wu and Yan-Shen Shan

Background: Acute pancreatitis (AP), a sudden inflammation of the pancreas, can cause severe complications and high mortality despite treatment. The use of mesenchymal stem cells (MSCs) for the treatment of AP has attracted significant attention in novel treatment strategy; however, the mode of action of spleen-derived MSCs (sp-MSCs) in AP remains unknown.
Method: MSCs isolated from mouse spleen (msp-MSCs) were used to investigate the effects in animal models of cerulean-induced acute pancreatitis (CAP) and pancreatic ischemia injury (PII).
Results: Msp-MSCs had multipotent differentiation capacities and immunoregulatory functions. A greater number of Qtracker-labeled msp-MSCs were detected in pancreas of mice with CAP than of control mice. Infused msp-MSCs reduced serum levels of amylase, lipase, and myeloperoxidase, and pancreatic edema, necrosis level, expression of inflammation cytokines, and CD3+T cell infiltration. In PII model, infused msp-MSCs promoted cell growth and thus improved pancreatic dysfunction.
Conclusion: Msp-MSCs exert protective effects on CAP- and PII-induced pancreatic injury and might be developed as a potential therapeutic agent for pancreatitis treatment.

免责声明: 此摘要通过人工智能工具翻译,尚未经过审核或验证